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Introduction
Osteoarthritis (OA) is a major cause of musculoskele-
tal pain that causes morbidity, physical and functional
limitation, and poor quality of life. OA of the knee is
the most common form of arthritis in older adults
and is an important community health care burden.1–3
OA of the knee is characterized by pain, stiffness, de-
creased joint range of motion, and increasing disabil-
ity. It can have an impact on several aspects of normal
life, such as function and social activity, relationships,
socioeconomic status, body image, and emotional well-
being. Due to the aging of the population, the preva-
lence and impact of the disease is projected to greatly
increase.4,5
The goals of symptomatic conservative therapies
are to reduce pain and maintain or improve function.6
Management options such as medication, local intra-
articular (IA) injection, physical modalities, exercise,
self-management programs, and surgery focus on pro-
viding symptom relief and maintaining function. Al-
though oral analgesics can achieve moderate reduction
of pain and slight functional improvement, they have
substantial limitations because they might not pro-
vide sufficient joint pain relief, often produce intoler-
able side effects, and can adversely interact with other
drugs.7 Several clinical trials have demonstrated the
effects of symptom-modifying drugs (such as glucos-
amine sulfate, chondroitin sulfate, doxycycline and dia-
cerein) in OA patients, but further experimentation is
ORIGINAL ARTICLE
Therapeutic Effects of Intra-articular Botulinum
Neurotoxin in Advanced Knee Osteoarthritis
Chen-Liang Chou1,2*, Si-Huei Lee1,2, Shin-Yo Lu1, Ko-Lun Tsai1, Chung-Yu Ho1, Hsuan-Chu Lai1
1Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, and 2Department of Physical
Medicine and Rehabilitation, National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
Background: Osteoarthritis (OA) is a major cause of musculoskeletal pain that causes morbidity, physical limitation, and
poor quality of life. The purpose of this study was to evaluate the therapeutic effects of intra-articular (IA) injection of 
botulinum neurotoxin A (BoNT/A) for advanced knee OA.
Methods: Twenty-four patients (38 knees) were enrolled, and the subjects were radiographically verified as having stage
III or IV OA according to the Kellgren–Lawrence classification. We used the Western Ontario and McMaster Universities
Osteoarthritis Index to evaluate the therapeutic effects monthly for 6 months. BoNT/A (100 U) was reconstituted with
4.0 mL saline and was injected into the symptomatic knee joints after baseline evaluation and 3 months later.
Results: The therapeutic effects of BoNT/A were clinically significant at 1 month after the first injection, but statistical
significance was not noted until 3 months after the first IA injection. Pain and stiffness improved clinically; however, the
effect of BoNT/A achieved statistical significance only for the pain subscale in stage III OA. There was no significant 
difference between the stage III and IV groups. There was no significant muscle atrophy or serious adverse effect in any
group after treatment.
Conclusion: IA BoNT/A provides a new therapeutic option for refractory pain in patients with advanced knee OA.
Although IA BoNT/A appears to be effective and safe for the management of advanced knee OA, these results cannot be
generalized to patients with mild knee joint pain or nonspecific soft tissue pain in the knee joint region. [J Chin Med
Assoc 2010;73(11):573–580]
Key Words: botulinum toxin type A, intra-articular injection, knee osteoarthritis
© 2010 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
*Correspondence to: Dr Chen-Liang Chou, Department of Physical Medicine and Rehabilitation,
Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.
E-mail: cl_chou@vghtpe.gov.tw ● Received: June 4, 2010 ● Accepted: July 30, 2010
required to confirm the effect of these dietary supple-
ments.8–10 There is also interest in the use of pulsed
electrical stimulation and electromagnetic fields as
potential OA disease-modifying treatments, but there
have been a limited number of studies on their effects
in humans.11–13 IA injection of hyaluronic acid for OA
knee pain is widely accepted, but the duration of its
effect is variable and sometimes results in inadequate
or unsatisfactory benefits.7,14,15 There are surgical in-
terventions with arthroscopic lavage and debridement
for refractory joint pain when medical therapies fail,
but the benefits of these procedures are still being
debated.16 Total joint arthroplasty for end-stage OA
is the only treatment option, and is effective in improv-
ing physical function and reducing pain in > 90% of
patients.17,18 However, surgery might be inappropriate
when the individual is too young or when the patients
experience too many comorbid conditions.7 It is nec-
essary to give these patients other treatments that re-
lieve chronic joint pain, improve joint function, and
avoid toxic effects caused by symptomatic therapy and
surgical complications, and surgical mortality. Such
treatment is especially beneficial for elderly patients.
One of the options for these patients is to receive IA
injections of botulinum neurotoxin type A (BoNT/A).
BoNT/A is effective for treatment of painful move-
ment disorders, spasticity, myofascial pain and condi-
tions with increased muscle tone, abnormal posture,
and pain.7,19–21 BoNT/A was initially used to de-
crease muscle tone and improve abnormal posturing
of the head or limbs. The above effects can also de-
crease pain. Later studies have demonstrated that the
analgesic effect of BoNT/A occurs earlier and to a
greater degree than decreased muscle tone. These
findings have led to speculation that the neurotoxin
might have effects on other systems beyond the neu-
romuscular junction.19,22,23
There have been only a few studies about the ther-
apeutic effects of IA BoNT/A in patients with knee
OA. In 1 preliminary joint pain study, patients with
general OA were selected.7 The purpose of our study
was to evaluate the therapeutic effect and safety of
BoNT/A in patients with advanced OA of the knees.
Methods
Patients
Only patients with advanced OA of the knee, radio-
graphically verified as stage III or IV according to the
Kellgren–Lawrence classification,24 were selected for
this study. The inclusion criteria were age > 60 years
with significant OA signs and symptoms in the knees,
and contraindications for surgical treatment because
of age or comorbidity, or both. Exclusion criteria were:
(1) significant inflammation of the OA joint; (2) pre-
vious IA injection of a steroid or any other invasive
procedure in the knee within the previous 6 months;
(3) history of IA knee fracture; (4) any other condition
that might have interfered with the efficiency assess-
ment or trial completion (such as oral analgesic drug
use or opioid injection, physical therapy for knee OA);
(5) any medical condition that might have increased the
risk to the subject of exposure to BoNT/A (such as
disorders that might have interfered with neuromus-
cular function); and (6) known allergy or sensitivity to
any component of the medication. All patients were
notified regarding IA injection of BoNT/A because
this is an off-label use that is not approved by the US
Food and Drug Administration, and BoNT/A injec-
tion has known side effects.
Study design
One hundred units of BoNT/A (Allergen Inc., Irvine,
CA, USA) were injected into the symptomatic OA
knee joint. One vial of BoNT/A (100 U) was recon-
stituted with 4.0 mL normal saline to a concentration
of 25 U/mL. All patients received 2 injections into
the joint, with a 3-month interval between injections.
The patients were evaluated before the first injection
and were monitored monthly thereafter for a total of
6 months.
The Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) was used to evaluate
the therapeutic effects at baseline (pre-injection) and
each month thereafter.25,26 The index included 3 di-
mensions, pain (5 questions), stiffness (2 questions),
and physical function (17 questions), which were rated
on an ordinal scale of 0 to 4. Lower scores indicated
lower levels of symptoms or physical disability. The
validation study reported internal consistency for the
pain, stiffness and physical function subscales of 0.86,
0.86 and 0.95, respectively.25 Reliability for the pain,
stiffness and physical function subscales was 0.68,
0.48 and 0.68, respectively.26 Thigh circumference at
5 cm above the midline of the patella, with the knee at
90° flexion, was measured to evaluate potential mus-
cle atrophy after IA injection of BoNT/A.
Statistical analysis
SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) was
used to evaluate the data. One-way analysis of variance
was used to calculate the differences between baseline
and the 6-month evaluations for pain, stiffness, physi-
cal function, and WOMAC scores. When significant
differences were found, the Bonferroni post hoc test was
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applied. To compare the differences between stages III
and IV at baseline, 3 months, and 6 months, the Mann–
Whitney U test was used to evaluate pain, stiffness,
physical function, and WOMAC scores. The Wilcoxon
signed rank test was used to evaluate the differences
between the WOMAC scores at 3 and 4 months. To
compare thigh circumferences at baseline, 3 months,
and 6 months, analysis of covariance was used to eval-
uate the differences. Results were considered statisti-
cally significant when the p values were < 0.05.
The study protocol was approved by the institu-
tional review board of the hospital, and all participants
provided signed, written informed consent before par-
ticipation. All patients were notified that IA injection
of BoNT/A was an off-label use of the drug and not
approved by the US Food and Drug Administration;
patients were also informed of the known side effects
of BoNT/A injection.
Results
Among the 24 study participants (Table 1), 38 knees
were studied. Two patients had bilateral OA, but the
knees were at different stages of OA; for the WOMAC
evaluation, these 2 patients were placed into the stage
IV group. The therapeutic effects of IA injection of
BoNT/A were clinically significant (Figures 1–4), but
statistical significance was not noted until 3 months
after the first BoNT/A injection. The effect lasted for
the entire month. The pain and stiffness subscales 
differed significantly from baseline (Table 2). In the
subgroup evaluation of IA BoNT/A, only the pain
subscale among stage III patients was statistically sig-
nificant at 3 months (Tables 3 and 4). There was gross
exacerbation of the therapeutic effect between 3 and
4 months (Figures 1–4). Thus, we compared the ther-
apeutic effect between the 3rd and 4th months for all
patients and stage III and IV groups; the therapeutic
effect did not differ significantly among the groups
(Tables 5 and 6). There was no significant quadriceps
muscle atrophy during the study (Table 7). There was
no serious systemic or local adverse effect in any group
during the 6-month follow-up period. Transient in-
jection site pain, mild joint swelling, or tenderness was
reported by 3 patients.
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Table 1. Basic patient data
Male/female 13/11
Mean age 73.38 ± 11.13 yr
Bilateral knee osteoarthritis
Stage III 9
Stage IV 3
Stage III/IV 2 (bilateral but different 
stages)
Unilateral knee osteoarthritis
Stage III 3
Stage IV 7
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Figure 1. WOMAC pain subscore (total of 38 knees). WOMAC =
Western Ontario and McMaster Universities Osteoarthritis Index;
SD = standard deviation; ANOVA = analysis of variance.
0
Injection
1-way ANOVA
p = 0.009
Injection
*p < 0.05 vs. baseline,
post hoc test
2
4
6
8
St
iff
ne
ss
 s
ub
sc
or
e
Mean SD
± 1.96 × SD
∗
∗
Baseline 1 2 3
Stiffness subscore (mo)
4 5 6
Figure 2. WOMAC stiffness subscore (total of 38 knees). WOMAC=
Western Ontario and McMaster Universities Osteoarthritis Index;
SD = standard deviation; ANOVA = analysis of variance.
Discussion
BoNT/A has been widely used to treat neurological
diseases of spasticity and other forms of muscle activ-
ity.27–33 Recently, it has been used to treat the chronic
pain of plantar fasciitis, myofascial pain syndrome,
tennis elbow, various types of headaches, and neuro-
pathic pain.34–39 The mechanism of pain reduction by
BoNT/A might include muscular relaxation (but dis-
sociation between pain relief and muscle relaxation
has been observed) and inhibition of neurotransmitter
release by sensory neurons.40–47
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Figure 3. WOMAC physical function subscore (total of 38 knees).
WOMAC=Western Ontario and McMaster Universities Osteoarthritis
Index; SD = standard deviation; ANOVA = analysis of variance.
Table 2. Therapeutic effect after intra-articular injection of botulinum neurotoxin A in all patients*
Baseline 1st mo 2nd mo 3rd mo 4th mo 5th mo 6th mo p†
Pain 10.96 ± 5.21 7.38 ± 5.40 6.88 ± 5.68 6.29 ± 4.61‡ 7.12 ± 4.43 5.17 ± 3.96‡ 5.21 ± 3.71‡ 0.000
Stiffness 4.17 ± 1.55 3.42 ± 1.89 2.88 ± 1.65 2.88 ± 1.68 2.88 ± 1.70 2.50 ± 1.50‡ 2.46 ± 1.84‡ 0.001
Physical 32.25 ± 15.21 28.50 ± 15.74 27.08 ± 15.96 26.33 ± 16.48 28.21 ± 16.67 26.46 ± 16.37 25.25 ± 15.99 0.019
function
Total 47.38 ± 18.72 39.29 ± 21.00 36.83 ± 21.14 35.50 ± 20.27 38.21 ± 20.88 34.12 ± 20.06 32.92 ± 20.02 0.000
WOMAC 
score
*Data are presented as mean ± standard deviation; †analysis of covariance; ‡significant difference compared with baseline (p < 0.05) by post hoc (Tukey’s 
honestly significant difference) test. WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
Table 3. Therapeutic effect after intra-articular injection of botulinum neurotoxin A in patients with stage III knee osteoarthritis*
Baseline 1st mo 2nd mo 3rd mo 4th mo 5th mo 6th mo p†
Pain 10.50 ± 4.01 7.67 ± 5.19 6.92 ± 5.53 6.08 ± 4.29 7.17 ± 4.45 4.67 ± 3.39‡ 4.92 ± 2.64‡ 0.045
Stiffness 4.17 ± 1.47 3.58 ± 1.78 3.08 ± 1.51 3.25 ± 1.76 2.92 ± 1.73 2.67 ± 1.67 2.50 ± 1.83 0.062
Physical 33.25 ± 17.53 29.33 ± 16.77 27.33 ± 17.35 27.92 ± 17.62 28.58 ± 17.38 27.08 ± 18.61 26.25 ± 17.99 0.247
function
Total 47.92 ± 21.77 40.58 ± 22.42 37.33 ± 22.20 37.25 ± 21.30 38.67 ± 21.87 34.42 ± 22.28 33.67 ± 20.83 0.064
WOMAC 
score
*Data are presented as mean ± standard deviation; †analysis of covariance; ‡significant difference compared with baseline (p < 0.05) by post hoc (Tukey’s 
honestly significant difference) test. WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
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Figure 4. WOMAC total score (total of 38 knees). WOMAC =
Western Ontario and McMaster Universities Osteoarthritis Index;
SD = standard deviation; ANOVA = analysis of variance.
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Table 4. Therapeutic effect after intra-articular injection of botulinum neurotoxin A in patients with stage IV knee osteoarthritis*
Baseline 1st mo 2nd mo 3rd mo 4th mo 5th mo 6th mo p†
Pain 11.42 ± 6.35 7.08 ± 5.82 6.83 ± 6.06 6.50 ± 5.09 7.08 ± 4.60 5.67 ± 4.56 5.50 ± 4.64 0.117
Stiffness 4.17 ± 1.70 3.25 ± 2.05 2.67 ± 1.83 2.50 ± 1.57 2.83 ± 1.75 2.33 ± 1.37 2.41 ± 1.93 0.113
Physical 31.25 ± 13.20 27.67 ± 15.34 26.83 ± 15.22 24.75 ± 15.86 27.83 ± 16.68 25.83 ± 14.61 24.25 ± 15.60 0.105
function
Total 46.83 ± 16.07 38.00 ± 20.39 36.33 ± 21.00 33.75 ± 19.97 37.75 ± 20.80 33.83 ± 18.57 32.17 ± 20.08 0.186
WOMAC 
score
*Data are presented as mean ± standard deviation; †analysis of covariance. WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
Table 5. Comparison of WOMAC score at 3 and 4 months after botulinum neurotoxin A therapy
p*
Pain Stiffness Physical function Total score
Total 0.144 1.000 0.418 0.210
Stage III 0.077 0.157 0.437 0.128
Stage IV 0.681 0.206 0.645 0.655
*Wilcoxon signed rank test. WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
Table 7. Comparison of thigh circumference in all patients (n = 38 knees)*
Baseline 3rd mo 6th mo p†
Thigh circumference 42.06 ± 6.53 42.31 ± 6.21 42.13 ± 6.76 0.984
*Data are presented as mean ± standard deviation; †1-way analysis of variance.
Table 6. Comparison of WOMAC score at baseline, and at 3 and 6 months after botulinum neurotoxin A therapy in patients with
stages III and IV knee osteoarthritis*
Stage III Stage IV p†
Pain subscore
Baseline 10.0 (7.3–13.0) 12.5 (4.3–17.0) 0.443
3rd mo 5.0 (2.3–10.0) 4.5 (2.3–10.8) 0.932
6th mo 4.5 (3.25–6.5) 5.0 (1.0–9.0) 0.977
Stiffness subscore
Baseline 4.0 (3.0–5.5) 4.0 (3.0–5.8) 0.977
3rd mo 3.0 (3.0–3.8) 2.0 (1.3–3.8) 0.291
6th mo 2.0 (1.0–3.0) 2.0 (1.0–4.8) 0.843
Physical function subscore
Baseline 33.5 (19.3–45.5) 29.5 (20.8–41.0) 0.887
3rd mo 25.0 (15.5–35.30 21.0 (13.5–39.5) 0.630
6th mo 23.0 (10.0–35.3) 22.0 (8.5–34.3) 0.713
Total WOMAC score
Baseline 49.0 (30.0–58.8) 44.0 (37.0–59.3) 0.932
3rd mo 34.0 (22.8–41.8) 33.0 (19.8–46.5) 0.755
6th mo 28.5 (16.8–44.0) 31.5 (14.0–47.3) 0.977
*Data are presented as median (25th–75th percentiles); †Mann–Whitney U test. WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
OA pain can come from many sites. The C-fiber
nociceptors form a diffuse lattice throughout the arti-
cular capsule, and A-δ fiber-free nerve endings are found
in IA and peri-articular ligaments.48,49 Substance P and
calcitonin gene-related peptide are found in nerve
fibers of the synovium.50 Increased neuropeptide syn-
thesis (substance P, calcitonin gene-related peptide,
dynorphin and enkephalin) is found in the dorsal gan-
glia and the spinal cord when joints are inflamed, which
causes joint pain.49,50 Peripheral sensitization such as
mechanical, thermal and chemical stimuli can cause
articular allodynia and hyperalgesia of sensitized arti-
cular primary afferent neurons. The spinal cord neurons
can be sensitized by sustained nociceptive afferent
input from a painful joint (central sensitization). The
peripheral and central sensitization amplifies nocicep-
tive processing.51–53 The direct analgesic effect of
BoNT/A on formalin-induced pain in mice was based
on the action of neurotransmitters other than acetyl-
choline; thus, it was independent of neuromuscular
junction blocking in cholinergic α motor neurons.54
BoNT/A suppresses OA pain.54–56 Nonetheless, in a
study of local inflammatory leg pain (not OA pain),
no anti-inflammatory or antinociceptive effect of
BoNT/A in human inflammatory pain was found,
despite highly promising data from animal research.40
In our study, IA BoNT/A treatment for advanced
OA knee pain significantly improved clinical pain and
stiffness, although the WOMAC scores for physical
function and total score were not significantly different
from baseline.
Several studies of the WOMAC have shown that it
is difficult for some patients to make distinctions be-
tween questions about pain (5 questions) and physical
function for activities of daily living (17 question).57,58
Additionally, the term “difficult”, as it is translated
from English to Chinese, might not have been clear
to some of our participants. For the subgroup evalua-
tion, only stage III OA knees had statistically significant
improvement in the pain subscale. This could have
been due to the small sample size in each group. In
future studies, sample size should be increased. The
therapeutic effect of BoNT/A did not differ between
the stage IV and/or III OA groups. Although total
knee arthroplasty has been suggested traditionally for
stage III and IV OA patients, IA BoNT/A could pro-
vide a new therapeutic option for patients in whom
such surgery is contraindicated.
Among our patients, therapeutic effect persisted after
a booster injection 3 months after the initial injection.
BoNT/A was injected intra-articularly for advanced
knee OA every 3 months to maintain the therapeutic
effect from month 3 till the end of the study. Hence,
it is implied that the therapeutic effect of BoNT/A is
transient rather than long-term.
There was a wide variation in the degree to which
knee pain was related to radiographic knee OA and vice
versa. OA severity (Kellgren–Lawrence classification,
stages III and IV) is a strong predictor of pain; the
greater the OA severity, the greater the knee pain.59
For evaluation of the therapeutic effect of IA BoNT/A
injection on knee OA pain, we selected only patients
with high-grade OA of the knee, and the therapeutic
effects of BoNT/A treatment did not differ between
stages III and IV OA. As mentioned before, there was
no significant change in the X-ray appearance of the
knee after BoNT/A injection. Additionally, thigh cir-
cumference did not significantly change during the
study. No significant muscle atrophy occurred with
the use of IA BoNT/A. Finally, because our patients
were all Taiwanese, we avoided potential racial and/
or ethnic bias in self-reporting disability data for OA
of the knee.2
There were some limitations in our study. This was
an open-label clinical trial with non-randomized treat-
ment allocation, which favors patient and observer bias.
Our subgroup sample size (stages III and IV) was
small, so the therapeutic effect was statistically signifi-
cant only for the WOMAC pain subscale in the stage
III OA group. We did not resolve the dose, dose-
duration and dilution effects for BoNT/A IA use.
Most OA patients describe experiencing notable fatigue
and indicate that this side effect has a substantial im-
pact on their lives.3 We did not evaluate the relation-
ship between pain, fatigue and quality of life. We did
not determine the baseline level of cartilage oligomeric
matrix protein, which is predictive of subsequent mag-
netic resonance imaging-determined cartilage loss in
knee OA.60 Future studies should include the mea-
surement of this biomarker. IA injection of BoNT/A
provides a new therapeutic option for refractory pain
among patients with advanced knee OA. Although IA
BoNT/A is effective and safe for the management of
chronic advanced knee OA, our results cannot be
generalized to patients with mild knee joint pain or
nonspecific soft tissue pain in the knee joint region.
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